Sectors ETFs Today Universe Correlation Playbook Watchlists Portfolios News Alerts Research Bots About

Daily digest

One email a day · alerts + bubble shifts · free during beta.

About Alerts Research Support ♡Disclosures Terms Privacy FR PT API Follow on X

US equities · Daily close · Refreshed nightly 22:30 Paris

Not investment advice. QuantAbundancia is educational research only. Nothing on this site is a recommendation to buy, sell, or hold any security. Past performance does not guarantee future results. Full disclosures.

We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.

News

High-signal headlines only — macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

3,464 signal articles · 310 in last 24h · 15,124 total before filter · latest 51m ago

310last 24h

1814last 7d

322🟢 bullish (7d)

187🔴 bearish (7d)

129publishers

All 🌍 Macro264 📊 Earnings922 🤝 M&A79 ⚖️ Regulatory20 🚀 Product14 📈 Analyst20

✕ clear all filtersticker: IOVASentiment:bullish neutral bearish ✓ showing all (incl. clickbait)

Zacks5d agobearish

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.

IOVA

MarketBeat5d agoneutral

Iovance Biotherapeutics Q1 Earnings Call Highlights

Iovance Biotherapeutics (NASDAQ:IOVA) reported first-quarter 2026 revenue of $71 million, up roughly 45% year-over-year, as the company pointed to rising demand for its tumor-infiltrating lymphocyte (TIL) therapy AMTAGVI and expanding commercial execution. Management also reiterated that recent manu

IOVA

Zacks6d agoneutral

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 0.00% and -7.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

IOVA

Zacks6d agoneutral

Alvotech (ALVO) Reports Q1 Loss, Lags Revenue Estimates

Alvotech (ALVO) delivered earnings and revenue surprises of -28.57% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

IOVA

Zacks7d agobearish

Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates

Ultragenyx (RARE) delivered earnings and revenue surprises of -18.96% and -15.66%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

IOVA

Zacks12d agobearish

Pacira (PCRX) Q1 Earnings Miss Estimates

Pacira (PCRX) delivered earnings and revenue surprises of -1.64% and +0.58%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

IOVA

Zacks13d agoneutral

Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IOVA

Zacks14d agoneutral

Regeneron (REGN) Surpasses Q1 Earnings and Revenue Estimates

Regeneron (REGN) delivered earnings and revenue surprises of +11.18% and +4.88%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

IOVA